Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918707 | 1.00 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL31326617 | 0.83 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL15088052 | 0.83 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL2853230 | 0.78 | — | — | |
| SCHEMBL29704485 | 0.78 | — | — | |
| SCHEMBL27943278 | 0.77 | — | — | |
| Iodide SCHEMBL27382621 | 0.77 | SIGMAR1 (0.40) | SIGMAR1CHRNB2CHRNA4 | |
| Isoquinoline SCHEMBL5124998 | 0.76 | CYP11B1 (0.38) | SIGMAR1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL56690 | 0.71 | TRPA1 (0.42) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL16031737 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248939-A | tyrosine amide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2019-09-17 | — | — | CN | claimed |
| CN-107735088-A | Histone deacetylase inhibitors, compositions and methods of use thereof | CHDI基金会股份有限公司 | 2018-02-23 | — | — | CN | claimed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | claimed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117561255-A | 3, 4-dihydro-2, 7-naphthyridine-1, 6 (2H, 7H) -dione compounds as MEK inhibitors | 辉瑞公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-107501275-B | It can be used as the compound of ATR kinase inhibitor | Votex Pharmaceutical Co., Ltd. (US) | 2019-11-22 | — | — | CN | disclosed |
| CN-107501274-B | It can be used as the compound of ATR kinase inhibitor | Votex Pharmaceutical Co., Ltd. (US) | 2019-11-22 | — | — | CN | disclosed |
| CN-109890797-A | It can be used as the substituted carbon nucleoside derivates of anticancer agent | 辉瑞公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-107735088-A | Histone deacetylase inhibitors, compositions and methods of use thereof | CHDI基金会股份有限公司 | 2018-02-23 | — | — | CN | disclosed |
| CN-107629059-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107629057-A | BET protein inhibitors and its application | 上海勋和医药科技有限公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107501274-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-107501275-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-104903325-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PRKAG1, PRKAG2, PRKAB1 | SIGMAR1 4770/4885CHRNB2 3597/4885CHRNA4 4061/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | SIGMAR1 1901/4885CHRNB2 1490/4885CHRNA4 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.